King Andrew James 4

What Happened

• Andrew James King, Chief Scientific Officer & Head of Research and Development at Jade Biosciences (JBIO), received equity awards reported on Feb 12, 2026. The filing shows 41,250 restricted stock units (RSUs) and a derivative award representing an option for 247,500 shares; both were recorded as acquisitions at $0.00 (typical for grants).

Key Details

• Transaction date: 2026-02-12; Form 4 filed 2026-02-13 (timely).
• Awards: 41,250 RSUs (F1) and a right/option to purchase 247,500 shares (F2).
• Price reported: $0.00 (grant/award), so no cash paid at grant.
• Vesting (per footnotes):
  • RSUs (F1): 1/4 vests on each of the first four anniversaries of Feb 15, 2026, subject to continued service; each RSU converts to one share when vested.
  • Option (F2): 25% vests Feb 15, 2027, remaining 75% vests in equal monthly installments over the following three years, subject to continued service.
• Shares owned after the transaction: Not specified in the provided excerpt of the filing.
• Transaction code: "A" (award/grant). No 10b5-1, tax-withholding, or late-filing notes present in the excerpt.

Context

• These are compensation awards (not open-market purchases or sales). RSUs and options are common executive compensation tools that create future equity only as they vest; they do not represent immediately tradable shares until vesting (RSUs convert to shares on vesting; options require exercise).
• Such grants are routine for executives and reflect compensation/retention, not an explicit buy/sell signal.